Table 3.
Disease characteristics based on KMT2Ar status
| KMT2A (n = 38) | Non-KMT2A (n = 382) | P | |
|---|---|---|---|
| Demographics | |||
| Median age at diagnosis, y (range) | 0.6 (0.02-11.1) | 8.5 (0.8-25.1) | <.0001 |
| Median age at infusion, y (range) | 3.0 (0.6-16.2) | 13.3 (1.7-30.4) | <.0001 |
| Female, n (%) | 16 (42.1) | 140 (36.6) | .6 |
| Male, n (%) | 22 (57.9) | 242 (63.4) | |
| Prior therapy (%) | |||
| Primary refractory | 7 (18.4) | 85 (22.2) | .68 |
| Prior HSCT | 18 (47.4) | 141 (36.9) | .22 |
| Prior blina | 12 (31.6) | 65 (17.0) | .04 |
| Prior blina nonresponse | 3 of 12 (25) | 31 of 65 (47.7) | .21 |
| Disease burden (%) | |||
| M1 | 17 (44.7) | 200 (52.4) | .4 |
| ≥M2 | 21 (55.3) | 182 (47.6) | |
| CAR type (%) | |||
| 41BB | 36 (94.7) | 329 (86.1) | .20 |
| CD28 | 2 (5.3) | 53 (13.9) | |
| CAR response (%)∗ | |||
| CR | 31 (86.1) | 345 (91.8) | .23 |
| No CR (PR/SD/PD) | 5 (13.9) | 31 (8.2) | |
| Relapse phenotype (%) | |||
| LS | 9 (23.7) | 3 (0.8) | <.0001 |
| CD19pos | 5 (13.2) | 78 (20.4) | |
| CD19neg | 1 (2.6) | 67 (17.5) | |
∗
Number of patients evaluable for response: KMT2A (n = 36); non-KMT2A (n = 376).